Brepocitinib Overview & RVT-3101 Update
RVT-3101: A Phase 3-Ready Anti-TLIA Antibody for Ulcerative Colitis, Crohn's
Disease and Other Indications
Statistically Significant and
Clinically Meaningful
Effects Seen in UC Phase 2b
•
•
High-end efficacy in all-comers population, statistically significant and clinically meaningful benefit at all doses tested
Response rates enriched in patients positive for a prospectively defined biomarker (~60% of UC patients)
Favorable safety and tolerability profile
Large and Well-Validated
Market Opportunity
RVT-3101 is First-in-class
with Large Data Set in Hand
Additional
Near-Term Catalyst
•
•
•
•
.
Both ulcerative colitis and Crohn's disease are large, well-validated commercial markets
Additional value creation potential expected outside of IBD
Robust dose ranging work to date: ~300 patients across four dose arms and two studies (including with SQ formulation)
Efficient Phase 3 program planned with clearly defined path to approval
Final UC Phase 2b data (TUSCANY-2) expected 1H 2023
Strong Intellectual
Property Position
•
•
Composition of matter IP protection until 2039+ (including extensions)
Biologic confers 12 years of regulatory exclusivity following approval
roivant
For investor audiences only
8View entire presentation